Drug therapy for the prevention of glucocorticoid induced osteoporosis in elderly patients: teriparatide or bisphosphonates?
Phase 4
- Conditions
- glucocorticoid-induced osteoporosis
- Registration Number
- JPRN-UMIN000009222
- Lead Sponsor
- Department of Rheumatology & Clinical Immunology,Saitama Medical Center, Saitama Medical Universitity
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have serious renal disorder (egfr < 35 ml /min or cr > 1.5 mg/ml). 2)Patient who has a history of renal stone past 5 years. 3)Patients with primary or secondary hyperparathyroidism. 4)Patients with hyperthyroidism or hypothyroidism. 5)Patients who are considered to be contraindicated for bisphosphonates or teriparatide. 6)Patients who are treated with warfarin. 7)Patients who have experiences of receiving drugs having influence on bone remodeling within 6 months at inclusion of the study (pth,bisphosphonates, estrogen , vitamin d3, vitamin k2, serm (raloxifene, bazedoxifene), calcitonin, Ipriflavone, steroids) 8) Patients who are thought to be inappropriate for this study by physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptomatic vertebral fractures, those are determined by conventional thoracic and spinal radiographs in lateral and antero-posterior projections at any time during study.
- Secondary Outcome Measures
Name Time Method on symptomatic vertebral fractures and non-vertebral fractures deetermined by plain X-ray. Bone mineral density values, those are measured at the lumbar spine. The serum levels of NTX, osteocalcin, 25(OH)vitamin D, growth hormone (GH) and IGF-1.